Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Phase II Study of Anti - Programmed Death - Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination With Chemotherapy for the First-Line Treatment of Unresectable Mesothelioma

NCT02899195 is registered in ClinicalTrials.gov with PrECOG, LLC. as lead sponsor.

NCT NCT02899195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02899195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Phase II Study of Anti - Programmed Death - Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination With Chemotherapy for the First-Line Treatment of Unresectable Mesothelioma
Lead sponsor
PrECOG, LLC.
Phase
Phase 2
Overall status
Completed
Start date
June 13, 2017
Completion date
June 29, 2023
Enrollment
55 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

mesothelioma, pleural mesothelioma